Study Type
Interventional - Drug
The objective of the REMIT-DAPA study was to determine if in patients with recently-diagnosed type 2 diabetes (T2DM), a 12-week course of forxiga, metformin, basal insulin glargine and lifestyle approaches will achieve drug-free diabetes remission in a higher proportion of patients than standard diabetes therapy at 24 weeks (three months after the drugs are stopped).
Participants will be randomized to two treatment groups:
a) a 12-week course of treatment with forxiga, metformin, insulin glargine and lifestyle therapy, and
(b) standard diabetes therapy, and followed for a total of 64 weeks.
Primary endpoint:
Diabetes remission evaluated at 24 weeks after randomization.
Interventional - Drug
Multicenter,open label RCT
1
6
154
2015 - 2018
PHRI
Back To Top